Nepal-made CAR-T cell therapy used to treat blood cancer patient
Summary
A 17-year-old blood cancer patient has been treated with Nepal-made CAR-T cell therapy for the first time at Tribhuvan University Teaching Hospital in Kathmandu. Doctors say the patient is stable, but will need a year of observation to assess the treatment’s full effect.
Key Points
- A 17-year-old blood cancer patient received Nepal-produced CAR-T cell therapy at Tribhuvan University Teaching Hospital for the first time in the country.
- Doctors said the patient’s condition is stable and early signs of effectiveness are encouraging, but full results will take about a year to confirm.
- The therapy targets CD19 and uses genetically modified T cells to attack cancer cells and reduce the risk of recurrence after chemotherapy.
- Researchers at the Centre for Regenerative Medicine Nepal described the development as a major breakthrough for cancer treatment in Nepal.
